Tofacit 5 mg tablet contains tofacitinib, a medicine that dampens specific immune signals involved in joint inflammation. It is used in adults with rheumatoid arthritis who have not responded well to other treatments.
There are 13 brands of Tofacitinib listed in Bangladesh. By unit price, Tofacit is among the cheapest of them.
What is Tofacit 5 mg Tablet?
Tofacit 5 mg is an immunosuppressant tablet containing tofacitinib, manufactured by Delta Pharma Limited. It works by blocking janus kinase (JAK) enzymes, which are involved in transmitting signals from inflammatory cytokines. This helps reduce inflammation and joint damage in rheumatoid arthritis. It is prescribed for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used alone or with other disease-modifying antirheumatic drugs. The dose and course are decided by the doctor.
Uses of Tofacit
Tofacit is indicated for adult patients with moderately to severely active rheumatoid arthritis who have not responded adequately to methotrexate or cannot tolerate it. It can be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). The doctor will determine if this medicine is appropriate for your condition.
How to use Tofacit
Tofacit is taken by mouth as a tablet. The exact dose, frequency, and duration of treatment are decided by your doctor based on your condition and response. Do not change the dose or stop taking it without consulting your doctor. If you have kidney or liver problems, your doctor may adjust the dose. Always follow your doctor's instructions carefully.
Side effects of Tofacit
Common side effects reported during the first three months of treatment include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis. More serious side effects can occur, such as serious infections, gastrointestinal perforations, and changes in laboratory parameters. Contact your doctor immediately if you experience signs of infection, severe abdominal pain, or any unusual symptoms.
Safety and precautions
Before starting Tofacit, tell your doctor if you have an active infection, a history of gastrointestinal perforation, or liver or kidney problems. Live vaccines should be avoided during treatment. Your doctor may monitor blood counts, liver enzymes, and lipids. Tofacit is pregnancy category C; use only if the potential benefit justifies the risk to the fetus. It is not known if tofacitinib passes into breast milk, so breastfeeding decisions should be made with your doctor. Keep out of reach of children and store below 30°C, protected from light and moisture.
Frequently asked questions
What is Tofacit used for and what kind of medicine is it?
Tofacit is an immunosuppressant used to treat moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate. It contains tofacitinib, which helps reduce inflammation and joint damage.
How should Tofacit be taken?
Tofacit is taken orally as a tablet. The dose and how often you take it are decided by your doctor, who will consider your condition and any kidney or liver problems. Never change the dose or stop treatment without your doctor's advice.
What side effects should I watch for and when should I call the doctor?
Common side effects include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis. Call your doctor right away if you have signs of infection, severe abdominal pain, or any unusual symptoms, as serious infections and gastrointestinal perforations can occur.
Rheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic ... Read moreRheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Pharmacology
Rheumatoid arthritis is an autoimmune disease characterized by a dysregulation of pro-inflammatory cytokines including IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Cytokines signalling results in tissue inflammation and joint damage by stimulating the recruitment and activation of immune cells via the janus kinase signalling pathway.
Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.
Dosage & Administration
Rheumatoid Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.
Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.
Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.
Interaction
Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.
Side Effects
The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with Tofacitinib monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.
Pregnancy & Lactation
Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother
Precautions & Warnings
Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections.
Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
Immunizations: Live vaccines: Avoid use with Tofacitinib.
Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.
Storage Conditions
Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.
Alternative brands of Tofacitinib
Other brands with the same generic name, cheapest first.